NewAmsterdam Pharma (NAMS) Receivables - Other (2023 - 2025)
NewAmsterdam Pharma (NAMS) has disclosed Receivables - Other for 3 consecutive years, with $6.8 million as the latest value for Q4 2025.
- Quarterly Receivables - Other rose 287.01% to $6.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.8 million through Dec 2025, up 287.01% year-over-year, with the annual reading at $6.8 million for FY2025, 287.01% up from the prior year.
- Receivables - Other hit $6.8 million in Q4 2025 for NewAmsterdam Pharma, up from $3.9 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $6.8 million in Q4 2025 to a low of $875000.0 in Q4 2023.
- Historically, Receivables - Other has averaged $2.9 million across 3 years, with a median of $2.1 million in 2024.
- Biggest YoY gain for Receivables - Other was 287.01% in 2025; the steepest drop was 63.81% in 2025.
- Year by year, Receivables - Other stood at $875000.0 in 2023, then skyrocketed by 99.77% to $1.7 million in 2024, then skyrocketed by 287.01% to $6.8 million in 2025.
- Business Quant data shows Receivables - Other for NAMS at $6.8 million in Q4 2025, $3.9 million in Q3 2025, and $3.3 million in Q2 2025.